Organ protection by helium gas inhalation: protective factors in the blood

Helium induced organ protection and the role of circulatory factors: secretion of Caveolin to the bloodstream

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

NL-OMON

Registry ID

NL-OMON26549

Enrollment

Registered

2014-04-13

Start date

2014-04-01

Completion date

Unknown

Last updated

2024-02-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ischemia/reperfusion injury ischemie/reperfusie schade

Interventions

- Inhalation of helium or air - Blood sampling by venous puncture

Eligibility

Inclusion criteria

Inclusion criteria: non-smoking, healthy male volunteers, aged 20-55 years

Exclusion criteria

Exclusion criteria: -Active smoking or smoking in the previous six months -Alcohol abuse or use of recreational drugs -Any allergic reaction on medication in the past -Presence of a chronic disease that is under current medical observation and needs pharmacological treatment, e.g. asthma, high blood pressure or diabetes

Design outcomes

Primary

Measure	Time frame
- Cell damage such as LDH, apoptosis markers - Expression of Cav-1 and Cav-3 in blood	—

Secondary

Measure	Time frame
- If Cav-levels are significantly different after helium inhalation, cells will be incubated with cav-antibodies	—

Contacts

Public ContactG.T.M.L. Oei

AMC Amsterdam

g.t.oei@amc.uva.nl06-14851585

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)